Cantitate/Preț
Produs

Immunotherapy of Renal Cell Carcinoma: Clinical and Experimental Developments

R.J.A. van Moorselaar Editat de Frans M. J. Debruyne, Ronald M. Bukowski, J. Edson Pontes, Pieter H. M. de Mulder
en Limba Engleză Paperback – 28 ian 1991
With contributions by numerous experts
Citește tot Restrânge

Preț: 70823 lei

Preț vechi: 74550 lei
-5% Nou

Puncte Express: 1062

Preț estimativ în valută:
13555 14098$ 11360£

Carte tipărită la comandă

Livrare economică 13-27 martie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783540528357
ISBN-10: 3540528350
Pagini: 160
Ilustrații: XI, 141 p. 8 illus.
Dimensiuni: 155 x 235 x 8 mm
Greutate: 0.23 kg
Editura: Springer Berlin, Heidelberg
Colecția Springer
Locul publicării:Berlin, Heidelberg, Germany

Public țintă

Research

Cuprins

Experimental Data.- Considerations in Immunotherapy of Genitourinary Neoplasia.- Murine Renal Cancer (Renca) Model: Background and Preclinical Studies.- Renal Cell Carcinoma: Experimental Metastases.- Oncogenes in Renal Cell Carcinoma.- Molecular Basis and Clinical Relevance of MDR1 Gene Expression in Renal Cell Carcinoma.- Radioimmunoconjugates in Renal Cell Carcinoma.- Interferon and Tumor Necrosis Factor in Renal Cell Carcinoma Model Systems.- Clinical Experience with Biological Response Modifiers in Renal Cell Carcinoma.- Rationale for Immunotherapy in Renal Cell Carcinoma.- Treatment of Renal Cell Carcinoma with Interferon.- Combination Therapy with Interferon in Renal Cell Carcinoma.- Recombinant Interferon Alpha Plus Vinblastine in Metastatic Renal Cell Cancer: Updated Results.- Monotherapy and Combination Therapy with Interferon-?, Interferon-?, and Tumor Necrosis Factor-? in Metastatic Renal Cell Carcinoma.- Treatment of Advanced Renal Cell Carcinoma by Systemic Low-Dose Recombinant Interleukin-2.- Direct Lymphatic Immunotherapy for Metastatic Renal Cell Carcinoma.- Combination Therapy of Renal Cell Carcinoma with Interleukin-2 and Interferon Alpha: The Cleveland Clinic Experience.- Tumor Infiltrating Lymphocytes in Human Renal Cell Carcinoma: Adoptive Immunotherapy and Characterization of Interleukin-2 Expanded Tumor-Infiltrating Lymphocytes.- Active Specific Immunotherapy in Renal Cell Carcinoma: Optimization.